Development Plan


Preclinical Studies Completion

BioRegenics, Inc., expects to complete preclinical studies for BioAct Matrix in both the femoral defect and spinal fusion models, combined with biocompatibility in 2026

Submit 510K Application to FDA

BioRegenics plans to submit device package for bone void filler for skeletal defects as well as spinal fusions in 2026

Receive FDA clearance as 510K


Clinical Studies Commence